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ABSTRACT 
 
VEGF and TGF-β1 induce angiogenesis but have opposing effects on endothelial cells. 
VEGF protects endothelial cells from apoptosis; TGF-β1 induces apoptosis. We have 
previously shown that VEGF / VEGF receptor-2 (flk-1) signaling mediates TGF-β1 
induction of apoptosis. This finding raised an important question: Does this mechanism 
stimulate or inhibit angiogenesis? Here we report that VEGF-mediated apoptosis is 
required for TGF-β1 induction of angiogenesis. In vitro the apoptotic effect of TGF-β1 
on endothelial cells is rapid and followed by a long period in which the cells are 
refractory to apoptosis induction by TGF-β1. Inhibition of VEGF / flk-1 signaling 
abrogates formation of vessel-like structures by TGF-β1 with an effect comparable to that 
of z-VAD, an apoptosis inhibitor. Similarly, genetic deficiency of VEGF abolishes TGF-
β1 upregulation of endothelial cell differentiation and formation of vascular structures in 
embryoid bodies. In vivo TGF-β1 induces endothelial cell apoptosis as rapidly as in vitro. 
Inhibition of VEGF blocks TGF-β1 induction of both apoptosis and angiogenesis, an 
effect similar to that of z-VAD. Thus, TGF-β1 induction of angiogenesis requires rapid 
and transient endothelial cell apoptosis mediated by VEGF/flk-1. This novel, unexpected 
role of VEGF and flk-1 indicates VEGF-mediated apoptosis as a potential target to control 
angiogenesis.  
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INTRODUCTION 
 
Angiogenesis, the formation of capillaries from preexisting blood vessels, 
occurs in a variety of physiological and pathological settings, including embryonic 
development, wound healing and tumor growth. A number of cytokines and growth 
factors modulate angiogenesis. Among them, vascular endothelial growth factor (VEGF) 
and transforming growth factor-beta 1 (TGF-β1) play prominent roles (Ferrara, 2004; 
Massague et al., 2000; Presta et al., 2005). VEGF controls a variety of endothelial cell 
functions involved in angiogenesis and protects endothelial cells from apoptosis (Hicklin 
and Ellis, 2005). VEGF transcription can be modulated by multiple stimuli (Levy et al., 
1995; Liu et al., 1995; Tischer et al., 1991), among which hypoxia plays a major role 
(Forsythe et al., 1996; Liu et al., 1995; Shweiki et al., 1992). In addition, cytokines and 
growth factors upregulate VEGF expression in a variety of cell types (Goldman et al., 
1993; Li et al., 1995; Pertovaara et al., 1994). Fibroblast growth factor-2 (FGF-2) and 
TGF-β1 induce VEGF expression in vascular endothelial cells (Ferrari et al., 2006; 
Seghezzi et al., 1998). VEGF activates two tyrosine kinase receptors, flt-1 (VEGFR-1) 
and flk-1 (VEGFR-2) (Hicklin and Ellis, 2005). Flk-1 has been implicated in endothelial 
cell proliferation and survival, and flt-1 in chemotaxis and vascular permeability (Gille et 
al., 2001; Keyt et al., 1996). VEGF, flk-1, and flt-1 are indispensable for angiogenesis 
and their genetic deficiency causes embryonic lethality as a result of blood vessels 
disorganization, endothelial cell overgrowth or impaired endothelial cell development 
(Carmeliet et al., 1996; Ferrara et al., 1996). In tumors VEGF expression correlates with 
tumor vascularity and progression. Inhibition of VEGF results in decreased tumor 
vascularity and growth, implicating VEGF as the major tumor angiogenesis factor 
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(Ferrara, 2004). Pharmacological treatments targeting VEGF or VEGFR-2 are currently 
used or in advanced clinical trials for the therapy of several malignancies (Ferrara, 2004; 
Ferrara and Kerbel, 2005).  
TGF-β1 is an important regulator of tissue morphogenesis and a potent 
inhibitor of proliferation for most cell types (Massague et al., 2000). Half of mice 
genetically deficient in TGF-β1 die in utero and show defective vasculogenesis, a 
phenotype consistent with abundant TGF-β1 gene expression in endothelial precursors 
(Dickson et al., 1995). TGF-β1 has multiple effects on vascular endothelial cells. In vivo 
TGF-β1 induces angiogenesis (Madri et al., 1988; Roberts et al., 1986; Yang and Moses, 
1990). However, in vitro it  inhibits endothelial cell proliferation (Pollman et al., 1999b), 
migration and proteolytic activity, opposes the stimulatory effect of FGF-2 on these 
endothelial cell functions (Pepper et al., 1990; Saksela et al., 1987), and downregulates 
flk-1 expression (Mandriota et al., 1996). Notably, TGF-β1 induces endothelial cell 
apoptosis, opposing the prosurvival activity of VEGF (Pollman et al., 1999a;b). 
Inhibition of apoptosis abrogates TGF-β1-induced angiogenesis in vitro (Choi and 
Ballermann, 1995), indicating that the apoptotic effect of TGF-β1 on endothelial cells is 
an important component of its angiogenic activity.  
During angiogenesis apoptosis is required for pruning the forming 
vascular network, and inhibition of apoptosis results in formation of abnormal vessels 
(Pollman et al., 1999a). In addition, apoptosis controls cell functions required for 
capillary morphogenesis in vitro and in vivo (Choi and Ballermann, 1995; Segura et al., 
2002). Because of its inhibitory effects on endothelial cells it has been proposed that 
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TGF-β1 induces angiogenesis in vivo through an indirect mechanism, by inducing 
expression of VEGF and/or other angiogenic factors in epithelial or other cell types 
(Pardali and Moustakas, 2007).  
VEGF and TGF-β1 are often co-expressed in tissues in which 
angiogenesis occurs, notably in a variety of tumors (Pardali and Moustakas, 2007). 
However, although numerous studies have investigated the mechanisms through 
which these individual growth factors control angiogenesis, their interactions at the 
level of endothelial cells are poorly understood. We have recently shown that TGF-β1 
upregulates endothelial cell expression of VEGF, and that TGF-β1 induction of 
endothelial cell apoptosis is mediated by activation of flk-1 by VEGF (Ferrari et al., 
2006). This finding raised an important question: Does this mechanism inhibit or 
stimulate blood vessel formation by TGF-β1? Here we report that VEGF-mediated 
apoptosis is required for TGF-β1 induction of angiogenesis in vitro and in vivo.  
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RESULTS 
Endothelial cell-derived VEGF controls TGF-β1 induction of in vitro angiogenesis  
TGF-β1 induces vascular endothelial cell expression of VEGF, which 
mediates the apoptotic activity of TGF-β1 through activation of flk-1 (Ferrari et al., 
2006). Because TGF-β1 induces angiogenesis in vitro and in vivo (Choi and Ballermann, 
1995; Segura et al., 2002; Yang and Moses, 1990), we hypothesized that endothelial cell 
VEGF also controls the angiogenic activity of TGF-β1. To test this hypothesis, confluent 
BCE cells grown on gelatin-coated dishes were incubated in the presence or absence of 
TGF- β1, and TGF-β1 was added to the medium every 24 h. Under these experimental 
conditions TGF-β1 induced apoptosis within 6 h to 12 h of incubation. Subsequently 
apoptosis decreased to control levels and further addition of TGF-β1 to the culture 
medium did not induce cell death (Fig. 1 A). In the absence of TGF-β1 the cells grew as a 
compact monolayer (Fig. 2 A, panel a). Addition of TGF-β1 to the culture medium 
induced formation of lumen-containing capillary-like structures (in vitro angiogenesis) 
within 72 h to 120 h (panel b), as described (Choi and Ballermann, 1995).  
We then characterized the effect of neutralizing anti-VEGF and anti-FGF-
2 antibodies on TGF-β1 induction of in vitro angiogenesis. VEGF antibody blocks the 
apoptotic activity of TGF-β1 on endothelial cells, whereas antibody to FGF-2 induces 
apoptosis in the presence or absence of TGF-β1 (Ferrari et al., 2006). Both antibodies 
blocked TGF-β1 induction of angiogenesis but with different effects. In the presence of 
VEGF antibody TGF-β1-treated cells (panel n) retained an intact monolayer. In contrast, 
addition of FGF-2 antibody to TGF- β1-treated cells caused massive cell death, with 
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sparse, disrupted capillary-like structures (panel k). This effect can be explained by our 
previous findings that anti-FGF-2 antibody induces endothelial cell apoptosis, and that 
FGF-2 -/- endothelial cells have higher apoptosis levels than wt cells (Ferrari et al., 2006).  
To analyze the role of apoptosis in TGF-β1 induction of in vitro 
angiogenesis we used z-VAD, a general caspase inhibitor that blocks apoptosis. z-VAD 
blocked induction of in vitro angiogenesis by TGF-β1 (Fig. 2, panel q) with an effect 
comparable to that of VEGF antibody. 
To characterize the role of VEGF receptors in TGF-β1 induction of in 
vitro angiogenesis we downregulated flt-1 and flk-1 by transient transfection of 
endothelial cells with specific siRNAs. Transfection with flk-1 or flt-1 siRNA resulted in 
strong downregulation of the expression of the respective receptor for up to 96 h, without 
affecting the level of the other (Fig. 3 A). Downregulation of flk-1 expression blocks 
TGF-β1 induction of endothelial cell apoptosis, whereas inhibition of flt-1 expression has 
no such effect (Ferrari et al., 2006). Flk-1 siRNA-transfected cells did not undergo 
apoptosis although they were treated with TGF-β1 every 24 h for up to 72 h (Fig. 3 B), 
showing that downregulation of flk-1 expression did not provide an apoptotic stimulus 
per se. However, transfection with flk-1 siRNA abrogated both the apoptotic effect of 
TGF-β1 (Fig. 3 B) and TGF-β1 induction of in vitro angiogenesis (Fig. 3 C and D). In 
contrast downregulation of flt-1 expression, which does not affect TGF-β1 induction of 
apoptosis (Ferrari et al., 2006), had no effect on in vitro angiogenesis (Fig. 3 C and D).  
The inhibitory effect of z-VAD and of antibodies to FGF-2 or VEGF on in 
vitro angiogenesis was rapidly reverted after removal of these reagents from the culture 
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medium (Fig. 2, panels l, o, r). Similarly, removal of TGF-β1 from the culture medium 
caused rapid reversion of the capillary-like structures into a monolayer (panels c, f, i), 
showing that the observed morphological changes did not reflect toxic effects of the 
reagents. Therefore, these results showed that endothelial cell apoptosis is an early event 
during induction of in vitro angiogenesis by TGF-β1, and both upregulation and 
downregulation of apoptosis block the in vitro angiogenic activity of TGF-β1. 
 
VEGF/flk-1 signaling mediates the effect of TGF-β1 on formation of vascular 
structures in embryoid bodies 
To study the role of VEGF signaling in TGF-β1 control of blood vessel 
formation we also used embryonic stem (ES) cells derived from wild-type (wt) mice and 
mice genetically deficient (KO) in either VEGF or flk-1 or flt-1. Under defined culture 
conditions ES cells form aggregates (embryoid bodies) and differentiate into all cell 
lineages (Wang et al., 1992). In embryoid bodies endothelial cells form a vascular 
network that can be identified by immunostaining with antibodies to endothelial cell 
markers such as ICAM-2, an endothelium-specific adhesion protein. Blood vessel 
formation in embryoid bodies mimics the development of the embryonic yolk sac 
vasculature; it occurs through both vasculogenesis and angiogenesis, and is modulated by 
a variety of growth factors and cytokines including VEGF and TGF-β1 (Bautch et al., 
2000; Bautch et al., 1996; Desbaillets et al., 2000; Feraud et al., 2001; Gualandris et al., 
2000b; Mallet et al., 2006; Ng et al., 2004). 
Consistent with previous reports (Gualandris et al., 2000b; Vittet et al., 
1996), wt embryoid bodies formed vascular structures that were increased by exogenous 
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VEGF; conversely, in the presence of exogenous TGF-β1 the endothelial cells formed 
thick cords (Fig. 4). In VEGF-deficient embryoid bodies endothelial cells were 
dramatically reduced in number and formed no vessel-like structures. Addition of 
exogenous VEGF to these cells restored the wt phenotype almost completely. In contrast, 
treatment with TGF-β1 had no such effect. Embryoid bodies from ES cells deficient in 
flt-1 showed a vascular phenotype comparable to that of wt embryoid bodies, and 
responded both to exogenous VEGF and TGF-β1 in a manner similar to wt embryoid 
bodies. Conversely, flk-1 KO embryoid bodies showed few endothelial cells that were 
sparse or formed occasional clusters but no vascular structures, and this phenotype was 
not corrected by addition of either VEGF or TGF-β1 (Fig. 4). Therefore, consistent with 
our results obtained by siRNA-mediated downregulation of VEGF receptors in mature 
endothelial cells (Fig. 4), these results indicated that the effect of TGF-β1 on embryoid 
body generation of vascular structures is mediated by VEGF. 
To confirm and quantitate this finding we analyzed ICAM-2 expression by 
RT-PCR and real-time PCR (Fig. 5). The results were similar to those obtained by 
studying ICAM-2 protein expression by immunofluorescence analysis. At day 9 of 
differentiation, when endothelial cell differentiation is complete (Balconi et al., 2000; 
Vittet et al., 1996), ICAM-2 mRNA expression was reduced 9.1-, 15.9- and 5.3-fold in 
VEGF-, flk-1- and flt-1-deficient embryoid bodies, respectively, relative to wt embryoid 
bodies. Both VEGF and TGF-β1 induced a nearly twofold increase of ICAM-2 mRNA 
levels in wt embryoid bodies. VEGF also increased ICAM-2 levels in VEGF KO 
embryoid bodies up to wt level. In contrast, TGF-β1 had no such effect, showing that the 
action of TGF-β1 on ICAM-2 expression is dependent on VEGF signaling. Addition of 
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VEGF or TGF-β1 had no significant effect on ICAM-2 mRNA levels in flt-1 KO and flk-
1 KO embryoid bodies.  
Thus, these results showed that TGF-β1 induction of endothelial cell 
differentiation (vasculogenesis) and angiogenesis requires VEGF signaling. 
 
VEGF mediates the apoptotic activity of TGF-β1 in vivo  
To assess the biological significance of our findings in vivo we tested the 
effect of neutralizing antibody to VEGF on TGF-β1 induction of endothelial cell 
apoptosis in the chicken embryo choriollantoic membrane (CAM). For this purpose we 
treated chicken embryo CAMs with TGF-β1 in the absence or presence of neutralizing 
VEGF antibody. We used a TGF-β1 concentration that induces angiogenesis in the CAM 
(Yang and Moses, 1990). After 6 h incubation we analyzed CAM sections by TUNEL 
and immunostaining with antibody to CD31, an endothelial cell marker. Analysis of the 
sections by confocal microscopy (Fig. 6) showed that TGF-β1 strongly upregulated the 
number of TUNEL-positive (apoptotic) cells in the CAM with an effect comparable to 
that of TNF-α, a potent inducer of endothelial cell apoptosis (Ferrari et al., 2006). 
Virtually all apoptotic cells colocalized with CD31-positive (endothelial) cells, consistent 
with previous reports that TGF-β1 selectively induces apoptosis in endothelial cells but 
not in smooth muscle cells or pericytes (Pollman et al., 1999b). VEGF antibody strongly 
downregulated the number of TUNEL-positive cells induced by TGF-β1, whereas control 
n.i. IgG had no such effect (Fig. 6). Thus, these results showed that TGF-β1 induction of 
endothelial cell apoptosis in vivo requires VEGF signaling. 
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 VEGF mediates TGF-β1 induction of angiogenesis in vivo  
We then tested the effect of neutralizing anti-VEGF antibody on TGF-β1 
induction of blood vessel formation in the CAM. As described (Yang and Moses, 1990), 
TGF-β1 induced formation of new capillaries from pre-existing CAM vessels with an 
effect comparable to that of FGF-2. The vessels formed in the presence of TGF-β1 were 
relatively large and had few branches, whereas those induced by FGF-2 were thin and 
had many branches (Fig. 7 A and B) (Yang and Moses, 1990). To confirm that our VEGF 
antibody neutralized chicken VEGF, we tested if it blocked angiogenesis induction in the 
CAM by FGF-2. We have previously shown that FGF-2 upregulates endothelial cell 
expression of VEGF, and that antibody to VEGF blocks FGF-2 induction of angiogenesis 
in vivo (Seghezzi et al., 1998). VEGF antibody blocked the angiogenic effect of FGF-2 in 
the CAM, showing that it neutralized chicken VEGF (Fig. 7 A and B). We therefore 
tested the effect of VEGF antibody on TGF-β1 induction of angiogenesis. TGF-β1 
increased the number of CAM vessels approximately 2.5-fold, an effect comparable to 
that obtained with FGF-2 and consistent with previous findings (Yang and Moses, 1990). 
Antibody to VEGF completely abrogated this effect, showing that TGF-β1 induces 
angiogenesis in vivo through the autocrine and/or paracrine action of VEGF.  
Because VEGF mediates the apoptotic activity of TGF-β1 on the CAM 
endothelial cells, these results indicated that the rapid apoptotic effect mediated by VEGF 
is required for TGF-β1 induction of angiogenesis in vivo. Therefore, we treated CAMs 
with TGF-β1 in the presence or absence of z-VAD, a general caspase inhibitor that 
blocks in vitro angiogenesis (Fig. 2, panel q). As shown in Figure 7 C and D, z-VAD 
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completely abrogated the angiogenic activity of TGF-β1 with an effect comparable to 
that of VEGF antibody. Thus, these results showed that rapid and transient upregulation 
of VEGF-flk-1-mediated endothelial cell apoptosis is required for TGF-β1 induction of 
angiogenesis in vivo. 
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DISCUSSION 
 
We have previously shown that the rapid induction of endothelial cell 
apoptosis by TGF-β1 is mediated by the autocrine or paracrine activation of VEGF 
receptor 2 (flk-1) by endothelial cell VEGF (Ferrari et al., 2006). However, a 
fundamental question remained to be answered: Does VEGF-mediated apoptosis promote 
or inhibit TGF-β1-induced angiogenesis? The data reported here show that that VEGF-
mediated apoptosis is an early event required for induction of blood vessel formation by 
TGF-β1. Therefore, endothelial cell apoptosis is not only necessary for pruning the 
forming vascular network during the late stages of angiogenesis; it also occurs in the 
initial steps of, and is required for angiogenesis to proceed. 
Our finding that TGF-β1-induced endothelial cell apoptosis is transient 
and followed by a long period in which the cells are refractory to the apoptotic effect of 
TGF-β1 can be explained by two non-mutually exclusive mechanisms: downregulation of 
TGF-β1 receptor (TGF-βR) expression, and inhibition of flk-1 expression (Anders et al., 
1997; Mandriota et al., 1996; Minami et al., 2001). Our observation is also consistent 
with a recent report that induction of endothelial cell death is followed by increased 
proliferation and resistance to apoptosis (Sakao et al., 2005). A variety of tumors contain 
high levels of both TGF-β1 and VEGF, which do not result in massive endothelial cell 
apoptosis. Our finding of the transient nature of TGF-β1-induced apoptosis, and the 
known effect of TGF-β1 on TGF-βR and flk-1 expression can explain the apparent lack 
of endothelial cell apoptosis in these tumors. 
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Under our experimental conditions siRNA-mediated downregulation of 
flk-1 expression did not result in endothelial cell apoptosis in vitro for at least 72 h, and 
inhibition of VEGF did not cause rapid endothelial cell apoptosis in vivo. These findings 
are seemingly in contrast with the well-established concept that VEGF/flk-1 signaling is 
required for endothelial cell survival in vitro and in vivo (Gerber et al., 1998a; Gerber et 
al., 1998b; Lee et al., 2007; Sweeney et al., 2002). However, several reports have shown 
that inhibition of VEGF – flk-1 signaling by antibodies or chemical inhibitors of the 
receptor does not cause rapid apoptosis of cultured endothelial cells in the absence of a 
pro-apoptotic stimulus (Geng et al., 2001; Lu et al., 2005; Sakao et al., 2007). The genetic 
deficiency of VEGF in cultured endothelial cells results in apoptosis only after 72 h 
incubation in serum-free medium, a pro-apoptotic culture condition (Gerber et al., 1998a; 
Gerber et al., 1998b; Lee et al., 2007). Our observation that downregulation of flk-1 
expression does not provide an apoptotic stimulus per se is also consistent with the recent 
finding that Notch-1 downregulates flk-1 expression without inducing endothelial cell 
apoptosis (Shawber et al., 2007). In addition, to the best of our knowledge, our previous 
(Ferrari et al., 2006) and present work is the first that tested the effect of siRNA-mediated 
downregulation of flk-1 expression on endothelial cell apoptosis. The specificity of the 
effect of the flk-1 siRNA we used is shown by its lack of downregulation of flt-1 
expression. Our finding that inhibition of VEGF - flk-1 signaling does not induce rapid 
endothelial cell apoptosis is also supported by our analysis of endothelial cell apoptosis in 
the CAM. In these experiments TGF-β1 induced endothelial cell apoptosis as rapidly (6 
h) as in vitro. Inhibition of VEGF by neutralizing antibody did not increase endothelial 
cell apoptosis in the presence of TGF-β1; on the contrary, it blocked the apoptotic effect 
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of TGF-β1. Based on our data we cannot exclude that inhibition of VEGF or flk-1 
expression for a longer time would result in apoptosis in the absence of TGF-β1. 
However, our results show that the rapid apoptotic effect of TGF-β1 on endothelial cells 
requires VEGF signaling and is necessary for the progression of the angiogenic process. 
Thus, VEGF-flk-1 signaling not only provides endothelial cells with pro-survival and 
proliferative/migratory stimuli required for vessel formation but also mediates the initial 
apoptotic effect necessary for TGF-β1 induction of angiogenesis. 
Inhibition of VEGF signaling – which blocks TGF-β1 induction of 
apoptosis - blocked in vitro angiogenesis with no apparent morphological changes in the 
endothelial cell monolayer. Conversely, inhibition of FGF-2 - which induces apoptosis - 
resulted in few scattered and disrupted capillary-like structures. Thus, both inhibition of 
and excess apoptosis block angiogenesis, indicating that an optimal level of apoptosis is 
required for vessel formation. 
Our experiments on the generation of vascular structures in embryoid 
bodies, a process that involves both vasculogenesis and angiogenesis, provide a genetic 
demonstration of the role of VEGF signaling in TGF-β1 induction of angiogenesis. 
Consistent with previous observations (Feraud et al., 2001; Gualandris et al., 2000b), 
both VEGF and TGF-β1 increased endothelial cell differentiation and formation of a 
vascular network in embryoid bodies. However, we found that TGF-β1 has no such effect 
on embryoid bodies genetically deficient in VEGF.  
A previous report has shown that TGF-β1 increases endothelial cell 
differentiation in a VEGF-independent manner and inhibits endothelial tube formation in 
 15
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
08
.1
75
8.
1 
: P
os
te
d 
2 
Ap
r 2
00
8
embryoid bodies (Mallet et al., 2006). Two reasons can explain this discrepancy with our 
results. The independence of TGF-β1 action from VEGF was shown by using a 
neutralizing antibody added a day 0 of differentiation; in contrast, we used cells 
genetically deficient in VEGF or VEGF receptors. In addition, the authors used PECAM 
as a marker of endothelial cell differentiation, whereas we used ICAM-2. These 
endothelial cell markers have different expression patterns during embryoid body 
differentiation. In differentiating embryoid bodies PECAM+ cells can be found that are 
not organized into vessels, suggesting that PECAM+ cells are endothelial cell precursors; 
conversely, ICAM-2+ cells are confined to patent vasculature (Bautch et al., 2000). 
The genetic deficiency of flk-1 caused a dramatic decrease in endothelial 
cell differentiation, which was not increased by either VEGF or TGF-β1. Thus, the very 
low number of endothelial cells in flk-1-deficient embryoid bodies did not allow any 
conclusion as to the role of flk-1 in TGF-β1 induction of vascular structures in embryoid 
bodies. However, our data obtained with ES cells genetically deficient in VEGF or flt-1 
are consistent with our results obtained with mature endothelial cells, showing the 
requirement of VEGF-flk-1 signaling for TGF-β1 control of endothelial cell 
differentiation and angiogenesis. This mechanism can therefore play a significant role in 
the control of endothelial stem cell differentiation during angiogenesis in vivo.  
Our findings that TGF-β1 induces apoptosis and angiogenesis in vitro and 
in vivo through the autocrine or paracrine activation of flk-1 by VEGF indicate a potential 
pharmacological approach to anti-angiogenesis therapy. High levels of VEGF, flk-1 and 
TGF-β1 are present in many tumors. Crosstalk between the signaling pathways activated 
by these growth factors controls endothelial cell apoptosis (Ferrari et al., 2006) and 
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angiogenesis. Understanding the mechanism(s) that modulate this crosstalk can permit 
the development of novel pharmacological tools to convert VEGF, a potent angiogenesis 
inducer and survival factor, into an inducer of uncontrolled endothelial cell apoptosis, and 
therefore into a potent anti-angiogenesis factor.  
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MATERIALS AND METHODS 
Materials. Human purified or recombinant TGF-β1, recombinant human or mouse 
VEGF, and rabbit neutralizing polyclonal antibodies to human or mouse VEGF were 
purchased from R&D Systems (Minneapolis, MN); z-VAD-(OMe)-FMK and DMSO 
from Sigma-Aldrich (St. Louis, MO). Polyclonal antibody to cleaved human caspase 3 
was purchased from Cell Signaling Technologies (Beverly, MA); polyclonal antibody to 
total ERK-2 from Santa Cruz Biotechnology (Santa Cruz, CA); anti-mouse CD31 
antibody from Pharmingen (San Jose, CA); mouse and rabbit non-immune IgG from 
Sigma-Aldrich, and human recombinant FGF-2 from Gibco BRL, Life Technologies, 
Inc., (Rockville, MD). Neutralizing monoclonal antibody to human FGF-2 (MAb 354FI) 
was a generous gift from Texas Biotechnology, Inc. (Houston, TX, USA). 
Cells and Media. Bovine capillary endothelial cells (BCE) and human umbilical vein 
endothelial cells (HUVE; Cascade Biologics, Portland, OR) were grown as described 
(Ferrari et al., 2006). 
Embryoid bodies. Wild-type mouse embryonic stem (ES) cells and embryonic mouse 
fibroblast cells (EMFI) established as described (Su et al., 1999) were provided to us by 
Dr. A. Joyner (Memorial Sloan-Kettering Institute, New York). ES cells genetically 
deficient in either VEGF or VEGFR-1 or -2 were provided to us by Drs. Andras Nagy 
(Samuel Lunenfeld Research Institute, Toronto, Canada) (Carmeliet et al., 1996), Janet 
Rossant (University of Toronto, Ontario, Canada) (Fong et al., 1995) and Guo-Hua Fong 
(University of Connecticut) (Fong et al., 1995), respectively. ES cell culture and 
differentiation into embryoid bodies were performed as described (Gualandris et al., 
2000a). 
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Western blotting. Western blotting was performed as described (Ferrari et al., 2006). 
siRNA transfection. Subconfluent HUVE cells were incubated with 200 pmol of human 
flk-1 or flt-1 siRNA oligonucleotides (Dharmacon RNA technologies, Lafayette, CO) and 
4 μl of Oligofectamine (Invitrogen, Carlsbad, CA) in serum-free medium for 4 h at 37° 
C, after which medium supplemented with 10% serum was added (Ferrari et al., 2006). 
The cells were used 48 h after transfection. 
Reverse transcription-polymerase chain reaction (RT-PCR). The following primers 
for human flk-1 and flt-1 were synthesized by IDT DNA technologies (Coralville, IA) 
based on the published sequences: 
flt1 (s: 5’CGACCTTGGTTGTGGCTGACT; a:5’CGGTTCTGGTTGGTGGCTTTG); 
flk1 (s: 5’ AACAAAGTCGGGAGAGGA; a:5’ TGACAAGAAGTAGCCAGAAGA);  
β-actin (s: 5’ATCTGGGACCAACCTTCTAGAATGAG;  
a: 5’CGTCATACTCCTGCTTGCTGATCCAC) 
Complementary DNA (cDNA) was synthesized from 1 µg of total RNA using 
SuperScript II RT (Invitrogen, Carlsbad, CA) and oligo-dT 3’ primer. Two µl of cDNA 
was amplified by PCR as described. 
Quantitative real-time PCR. Total RNA was reverse transcribed with Superscript II 
(Invitrogen) using oligo dT and analyzed for transcript levels using the BioRad Icycler iQ 
Real-Time Detection System. Primer and probe oligonucleotides were obtained from IDT 
and Sigma Genosys, respectively, for β-actin and ICAM-2 as follows: 5’ATG TTG GAA 
GAG CAT CCT CAA GG3’ (ICAM-2 Forward), 5’GGC TGG TAC ACC CTG ATG 
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TTG3’ (ICAM-2 Reverse), 5’CCG AGT GCT GCT TTC CCG AAC ACG3’ (ICAM-2 
Probe); 5’GGA AAT CGT GCG TGA CAT CAA AG3’ (actB Forward), 5CGT CAC 
ACT TCA TGA TGG AAT TG3’ (actB Reverse), and 5’GAT GCC ACA GGA TTC 
CAT ACC CAA G3’ (actB Probe). Probes were 5’ labeled with the reporter fluorophore 
6-FAM and 3’ with the quencher BHQ-1. ICAM-2 and β-actin PCR amplicons were 
cloned into the PCR-TOPO vector (Invitrogen), and used as standards for qPCR at a 
plasmid copy number of 7.6×106. Quantitative PCR was performed for 50 cycles using a 
two-step protocol with a 58oC annealing temperature, and analyzed for threshold cycle. 
In vitro angiogenesis. Confluent endothelial cells grown in gelatin-coated tissue culture 
plates were incubated in medium containing 0.5% donor calf serum with or without 
addition of TGF-β1 (1 ng/ml) and/or the indicated reagents. The cultures were 
photographed with an inverted phase contrast microscope (Zeiss Axiovert 25) after the 
indicated time of incubation. Quantification was performed by using an ocular grid and 
counting the number of capillary-like structures that crossed the equatorial line of the 
microscope field in five randomly chosen 10 X fields per sample. Each sample was 
analyzed in triplicate. 
In vivo apoptosis and angiogenesis assays on the chick chorioallantoic membrane 
(CAM). Angiogenesis assays were performed as described (Brooks et al., 1999) using 
filter disks soaked with hydroxycortisone acetate (Sigma; 2.5 mg/ml in 95% ethanol). To 
characterize endothelial cell apoptosis CAMs were separated from the paper disks after 6 
h incubation at 38o C and snap frozen in OTC. Four-micrometer sections were cut and 
stained with antibodies to CD31 and with the FragEL DNA Fragmentation Kit for 
TUNEL analysis (Calbiochem; San Diego, CA), and counterstained with DAPI. The 
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sections were observed under a confocal microscope, and TUNEL-positive cells were 
counted in ten 100X fields. Five CAMs per sample were used. To characterize 
angiogenesis CAMs were incubated at 38o C for 72 h, and the number of branching blood 
vessels within the area of the filter disks was counted by stereomicroscopy as described 
(Brooks et al., 1999). Eight CAMs per condition were used. The CAMs were 
photographed with a digital camera connected to the microscope.  
Statistical Analysis. t-tests on the equality of means were performed using Stata 8. 
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FIGURE LEGENDS 
Figure 1. Induction of endothelial cell apoptosis by TGF-β1. Western blotting analysis 
of caspase 3 cleavage in BCE cells incubated in the absence or presence of TGF-β1 (1 
ng/ml) for the indicated time. TGF-β1 was added to the culture medium every 24 h 
(arrows). ERK-2: loading control.  
Figure 2. In vitro angiogenesis. A. Confluent BCE cells grown in gelatin-coated dishes 
were incubated in the absence (left column) or presence of TGF- β1 (1 ng/ml; middle 
column) in medium supplemented with either 50 μg/ml of mouse n.i. IgG or antibodies to 
VEGF (a-VEGF) or FGF-2 (a-FGF-2), or with 40 μM z-VAD-(OMe)-FMK (z-VAD) or 
0.2 % (v/v) DMSO (vehicle), or with no addition (Control). The cultures were stained 
with Giemsa photographed after 72 h incubation. The medium was then replaced with 
medium with no TGF-β1 (right column, top three panels) or with medium containing 
TGF-β1 and n.i IgG instead of FGF-2 or VEGF MAbs, or DMSO instead of z-VAD 
(right column, bottom three panels, respectively). After 24 h incubation the cultures were 
stained with hematoxylin-eosin and photographed. Bar represents 200 μm. This 
experiment was repeated three times with comparable results. B. The results of the 
experiments shown in panel A were quantitated as described under Methods. The 
histograms represent mean ± SE. p < 0.05 (sample vs. control). 
Fig. 3. Downregulation of flk-1 expression blocks TGF-β1 induction of apoptosis in 
vitro. A. RT-PCR analysis of flt-1 and flk-1 mRNA expression in HUVEC transfected 
with flt-1 or flk-1 siRNA. The cells were analyzed at the indicated time after siRNA 
transfection. Actin: loading control. B. Western blotting analysis of caspase-3 cleavage 
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(Cl-Csp) in HUVEC transfected with flk-1 siRNA or mock-transfected and treated with 
control medium (C) or TGF-β1 (1 ng/ml) for the indicated time. TGF-β1 was added to 
the culture medium every 24 h. ERK-2: loading control. C. Confluent HUVEC grown in 
gelatin-coated dishes and either non transfected (a) or transfected with transfection 
reagent alone (b) or with flt-1 (c) or flk-1 (d) siRNAs. The cells were photographed after 
96 h incubation in the absence (a) or presence (b-d) of TGF-β1 (1 ng/ml). Bar represents 
100 μm. This experiment was repeated three times with comparable results. D. The 
results of the experiments shown in panel A were quantitated as described under 
Methods. The histograms represent mean ± SE. p < 0.05 (sample vs. control). 
Figure 4. VEGF signaling mediates the effect of TGF-β1 on formation of vascular 
structures in embryoid bodies. Embryonic stem cells from wt or VEGF- (VEGF KO) or 
flk-1-deficient (flk-1 KO) mice were induced to differentiate in the absence (-) or 
presence of VEGF (30 ng/ml) or TGF-β1 (1 ng/ml). After 9-days incubation the 
differentiated cultures (embryoid bodies) were stained with rhodamine-labeled antibody 
to ICAM-2, an endothelial cell marker, and photographed with a fluorescence 
microscope. VEGF enhanced the formation of vascular networks in wt and VEGF-
deficient embryoid bodies but not in flk-1-deficient embryoid bodies. Addition of TGF-
β1 remodeled the capillary network in wt embryoid bodies, but had no such effect on 
VEGF- or flk-1-deficient endothelial cells. Bar represents 200 μm. 
Figure 5. The genetic deficiency of VEGF or flk-1 abrogates TGF-β1 induction of 
endothelial cell differentiation in embryoid bodies. A. RT-PCR analysis. Embryonic 
stem cells from wt, VEGF- (VEGF KO) and flk-1-deficient (flk-1 KO) mice were 
induced to differentiate in the absence (-) or presence of VEGF (30 ng/ml) or TGF-β1 (1 
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ng/ml). After 9-days incubation the differentiated cultures (embryoid bodies) were 
analyzed for ICAM-2 expression. β-actin: loading control.  (-RT) RT-PCR negative 
control. B. Quantitative Real Time PCR. The histograms show ICAM-2 fold change 
relative to untreated wt embryoid bodies. All values were normalized to β-actin 
expression. 
Figure 6. Inhibition of VEGF signaling blocks TGF-β1 induction of endothelial cell 
apoptosis in vivo. Confocal micrographs (100 X) of CAMs incubated for 6 h with either 
PBS (Control) or TGF-β1 (100 ng) in the presence or absence of isotype-matched non-
immune IgG or anti-mouse VEGF antibody (5 μg). A CAM incubated with TNF-α (100 
ng + 1 mg of cycloheximide) is shown as a positive control for apoptosis. CD31-positive 
endothelial cells are stained in red, TUNEL-positive cells are stained in yellow-green. 
The CAMs were counterstained with DAPI to reveal all nuclei in the section. Merge: 
high-power (200 X) images of the same field with merged DAPI and CD31 staining and 
with TUNEL staining shows colocalization of TUNEL-positive cells with CD31-positive 
cells. Filter disks soaked with hydroxycortisone acetate (Sigma; 2.5 mg/ml in 95% 
ethanol) plus or minus the indicated reagents were applied on 10-day old CAMs as 
described (Brooks et al., 1999). After 6 h incubation at 38o C the CAMs were separated 
from the paper disks, snap frozen in OTC and 4 μm sections were cut. Five CAMs per 
sample were used. B. TUNEL-positive cells colocalized with CD31-positive cells were 
counted in low-power (100 X) fields of sections from all the five CAMs of each sample. 
The histogram shows mean number of TUNEL-positive nuclei / field ± s.d. * p < 0.01 
(sample vs. control). 
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Figure 7. A and B. Inhibition of VEGF signaling blocks TGF-β1 induction of 
angiogenesis in vivo. A. Chorioallantoic membranes of 10-day old chicken embryos 
incubated with either hrFGF-2 (50 ng) or hrTGF-β1 (100 ng) or with control medium 
(DMEM) in the absence (-) or presence of 5 μg of anti-mouse VEGF antibody (VEGF 
Ab) or n.i. IgG. Representative images from one experiment are shown. Arrowheads 
indicate newly formed branching vessels. B. Number of branching new vessels in CAMs 
treated with the indicated reagents as described above. The histograms represent mean ± 
SE of the number of vessels/CAM determined in three independent experiments (8 
CAMs/sample/experiment). *: p < 0.05 (sample vs. control). C. and D. Inhibition of 
apoptosis blocks TGF-β1 induction of angiogenesis in vivo. C. Chorioallantoic 
membranes of 10-day old embryos untreated (Control), treated with z-VAD-(OMe)-FMK 
(z-VAD) or incubated with TGF-β1 alone or with TGF-β1 and z-VAD. D. Number of 
branching new vessels in CAMs treated with the indicated reagents as described above. 
The histograms represent mean ± SE of the number of vessels/CAM determined in three 
independent experiments (8 CAMs/sample/experiment). *: p < 0.05 (sample vs. control). 
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